Journal of Current Glaucoma Practice

Register      Login

VOLUME 8 , ISSUE 2 ( May-August, 2014 ) > List of Articles


Wound Healing Modulation in Glaucoma Filtration Surgery–Conventional Practices and New Perspectives: The Role of Antifibrotic Agents (Part I)

Jennifer C Fan Gaskin, Dan Q Nguyen, Ghee Soon Ang, Jeremy O'Connor, Jonathan G Crowston

Keywords : Glaucoma, Trabeculectomy, Filtration surgery, Antimetabolites, Wound healing modulation, Scarring

Citation Information : Fan Gaskin JC, Nguyen DQ, Soon Ang G, O'Connor J, Crowston JG. Wound Healing Modulation in Glaucoma Filtration Surgery–Conventional Practices and New Perspectives: The Role of Antifibrotic Agents (Part I). J Curr Glaucoma Pract 2014; 8 (2):37-45.

DOI: 10.5005/jp-journals-10008-1159

License: CC BY-NC 4.0

Published Online: 01-06-2019

Copyright Statement:  Copyright © 2014; The Author(s).


Glaucoma filtration surgery is regularly performed for the treatment of glaucoma and trabeculectomy is often regarded as the ‘gold standard’ glaucoma operation. The biggest risk of failure of the operation is bleb scarring. The advent of anti-fibrotic agents, such as mitomycin C (MMC) and 5-fluorouracil (5FU) has vastly prolonged the longevity of the bleb, but concerns remain regarding the potential increase in postoperative complications. More selective therapeutic targets have therefore been explored. One of these is vascular endothelial growth factor (VEGF) inhibition. Vascular endothelial growth factor inhi bition has a role not only in sub conjunctival angiogenesis inhi bition but also it has direct anti-fibrotic properties. Newer phar macological compounds and materials have also been developed in recent years in attempt to modulate the wound healing in different ways after glaucoma surgery. These include physical barriers to scarring and vehicles for sustained release of pharmacological agents, and early promising results have been demonstrated. This two-part review will provide a discussion of the application of anti-fibrotic agents in glaucoma filtration surgery and evaluate the newer agents that have been developed.

PDF Share
  1. Chen CW. Enhanced intraocular pressure controlling effectiveness of trabeculectomy by local application of mitomycin C. Trans Asia-Pacific Acad Ophthalmol 1983;9:172-177.
  2. Gressel MG, Parrish RK 2nd, Folberg R. 5-fluorouracil and glaucoma filtering surgery: I. An animal model. Ophthalmology 1984 Apr;91(4):378-383.
  3. Cordeiro MF, Schultz GS, Ali RR, Bhattacharya SS, Khaw PT. Molecular therapy in ocular wound healing. Br J Ophthalmol 1999 Nov;83(11):1219-1224.
  4. Skuta GL, Parrish RK 2nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol 1987 Nov-Dec;32(3):149-170.
  5. Loon SC, Chew PT. A major review of antimetabolites in glaucoma therapy. Ophthalmologica 1999;213(4):234-245.
  6. Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci 1998 Feb;39(2):449-454.
  7. Crowston JG, Chang LH, Constable PH, Daniels JT, Akbar AN, Khaw PT. Apoptosis gene expression and death receptor signaling in mitomycin-C-treated human tenon capsule fibroblasts. Invest Ophthalmol Vis Sci 2002 Mar;43(3):692-699.
  8. Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol 1993 Feb;111(2):263-267.
  9. Nakamura M, Yamamoto M. DNA interstrand crosslinking agents and human ocular fibroblasts: differential sensitivity to mitomycin-C and cis-diaminedichloroplatinum(II). Exp Eye Res 1994 Jul;59(1):53-62.
  10. Lee DA, Lee TC, Cortes AE, Kitada S. Effects of mithramycin, mitomycin, daunorubicin and bleomycin on human subconjunctival fibroblast attachment and proliferation. Invest Ophthalmol Vis Sci 1990 Oct;31(10):2136-2144.
  11. Skuta GL, Beeson CC, Higginbotham EJ, Lichter PR, Musch DC, Bergstrom TJ, Klein TB, Falck FY Jr. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology 1992 Mar;99(3):438-444.
  12. Falck FY Jr, Skuta GL, Klein TB. Mitomycin versus 5-fluorouracil antimetabolite therapy for glaucoma filtration surgery. Semin Ophthalmol 1992;7:97-109.
  13. Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology 1991 Mar;98(3):317-321.
  14. Mostafaei A. Augmenting trabeculectomy in glaucoma with subconjunctival mitomycin C versus subconjunctival 5-fluorouracil: a randomized clinical trial. Clin Ophthalmol 2011;5:491-494.
  15. El Sayyad F, Belmekki M, Helal M, Khalil M, El-Hamzawey H, Hisham M. Simultaneous subconjunctival and subscleral mitomycin-C application in trabeculectomy. Ophthalmology 2000 Feb;107(2):298-301.
  16. Prata JA Jr, Minckler DS, Baerveldt G, Lee PP, Heuer DK. Site of mitomycin-C application during trabeculectomy. J Glaucoma 1994;3(4):296-301.
  17. Gandolfi SA, Vecchi M, Braccio L. Decrease of intraocular pressure after subconjunctival injection of mitomycin in human glaucoma. Arch Ophthalmol 1995 May;113(5):582-585.
  18. Mietz H, Addicks K, Diestelhorst M, Krieglstein GK. Extraocular application of mitomycin C in a rabbit model: cytotoxic effects on the ciliary body and epithelium. Ophthalmic Surg 1994 Apr;25(4):240-244.
  19. Kee C, Pelzek CD, Kaufman PL. Mitomycin C suppresses aqueous humor flow in cynomolgus monkeys. Arch Ophthalmol 1995 Feb;113(2):239-242.
  20. Georgopoulos M, Vass C, El Menyawi I, Radda S, Graninger W, Menapace R. In vitro diffusion of mitomycin-C into human sclera after episcleral application: impact of diffusion time. Exp Eye Res 2000 Nov;71(5):453-457.
  21. Vass C, Georgopoulos M, el Menyawi I, Radda S, Nimmerrichter P. Intrascleral concentration vs depth profile of mitomycin-C after episcleral application: impact of applied concentration and volume of mitomycin-C solution. Exp Eye Res 2000 May;70(5):571-575.
  22. Cheung JC, Wright MM, Murali S, Pederson JE. Intermediateterm outcome of variable dose mitomycin C filtering surgery. Ophthalmology 1997 Jan;104(1):143-149.
  23. Lee SJ, Paranhos A, Shields MB. Does titration of mitomycin C as an adjunct to trabeculectomy significantly influence the intraocular pressure outcome? Clin Ophthalmol 2009;3:81-87.
  24. Perkins TW, Gangnon R, Ladd W, Kaufman PL, Heatley GA. Trabeculectomy with mitomycin C: intermediate-term results. J Glaucoma 1998 Aug;7(4):230-236.
  25. Megevand GS, Salmon JF, Scholtz RP, Murray AD. The effect of reducing the exposure time of mitomycin C in glaucoma filtering surgery. Ophthalmology 1995 Jan;102(1):84-90.
  26. Neelakantan A, Rao BS, Vijaya L, Grandham SB, Krishnan N, Priya VS, Murugeshan R. Effect of the concentration and duration of application of mitomycin C in trabeculectomy. Ophthalmic Surg 1994 Sep-Oct;25(9):612-615.
  27. Kim YY, Sexton RM, Shin DH, Kim C, Ginde SA, Ren J, Lee D, Kupin TH. Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycin C. Am J Ophthalmol 1998 Dec;126(6):755-762.
  28. Robin AL, Ramakrishnan R, Krishnadas R, Smith SD, Katz JD, Selvaraj S, Skuta GL, Bhatnagar R. A long-term doseresponse study of mitomycin in glaucoma filtration surgery. Arch Ophthalmol 1997 Aug;115(8):969-974.
  29. Vass C, Georgopoulos M, El Menyawi I, Radda S, Nimmerrichter P, Menapace R. Intrascleral concentration vs depth profile of mitomycin-C after episcleral application: impact of irrigation. Exp Eye Res 2000 Feb;70(2):139-143.
  30. Kirwan JF, Lockwood AJ, Shah P, Macleod A, Broadway DC, King AJ, McNaught AI, Agrawal P. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology 2013 Dec;120(12):2532-2539.
  31. Edmunds B, Thompson JR, Salmon JF, Wormald RP. The National Survey of Trabeculectomy. II. Variations in operative technique and outcome. Eye (Lond) 2001 Aug;15(Pt 4):441-448.
  32. Joshi AB, Parrish RK 2nd, Feuer WF. 2002 survey of the American Glaucoma Society: practice preferences for glaucoma surgery and antifibrotic use. J Glaucoma 2005 Apr;14(2):172-174.
  33. Reibaldi A, Uva MG, Longo A. Nine-year follow-up of trabeculectomy with or without low-dosage mitomycin-C in primary open-angle glaucoma. Br J Ophthalmol 2008 Dec;92(12):1666-1670.
  34. Fontana H, Nouri-Mahdavi K, Lumba J, Ralli M, Caprioli J. Trabeculectomy with mitomycin C: outcomes and risk factors for failure in phakic open-angle glaucoma. Ophthalmology 2006 Jun;113(6):930-936.
  35. Beckers HJ, Kinders KC, Webers CA. Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol 2003 Feb;241(2):106-110.
  36. Shigeeda T, Tomidokoro A, Chen YN, Shirato S, Araie M. Long-term follow-up of initial trabeculectomy with mitomycin C for primary open-angle glaucoma in Japanese patients. J Glaucoma 2006 Jun;15(3):195-199.
  37. Mills KB. Trabeculectomy: a retrospective long-term follow-up of 444 cases. Br J Ophthalmol 1981 Nov;65(11):790-795.
  38. Levene RZ. Glaucoma filtering surgery: factors that determine pressure control. Ophthalmic Surg 1984 Jun;15(6):475-483.
  39. Jacobi PC, Dietlein TS, Krieglstein GK. Adjunctive mitomycin C in primary trabeculectomy in young adults: a long-term study of case-matched young patients. Graefes Arch Clin Exp Ophthalmol 1998 Sep;236(9):652-657.
  40. Membrey WL, Poinoosawmy DP, Bunce C, Hitchings RA. Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 1 intraocular pressure control and complications. Br J Ophthalmol 2000 Jun;84(6):586-590.
  41. Membrey WL, Bunce C, Poinoosawmy DP, Fitzke FW, Hitchings RA. Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 2 Visual field progression. Br J Ophthalmol 2001 Jun;85(6):696-701.
  42. Mandal AK, Walton DS, John T, Jayagandan A. Mitomycin C-augmented trabeculectomy in refractory congenital glaucoma. Ophthalmology 1997 Jun;104(6):996-1003.
  43. Sidoti PA, Belmonte SJ, Liebmann JM, Ritch R. Trabeculectomy with mitomycin-C in the treatment of pediatric glaucomas. Ophthalmology 2000 Mar;107(3):422-429.
  44. al-Hazmi A, Zwaan J, Awad A, al-Mesfer S, Mullaney PB, Wheeler DT. Effectiveness and complications of mitomycin C use during pediatric glaucoma surgery. Ophthalmology 1998 Oct;105(10):1915-1920.
  45. Mandal AK, Bagga H, Nutheti R, Gothwal VK, Nanda AK. Trabeculectomy with or without mitomycin-C for paediatric glaucoma in aphakia and pseudophakia following congenital cataract surgery. Eye (Lond) 2003 Jan;17(1):53-62.
  46. Azuara-Blanco A, Wilson RP, Spaeth GL, Schmidt CM, Augsburger JJ. Filtration procedures supplemented with mitomycin C in the management of childhood glaucoma. Br J Ophthalmol 1999 Feb;83(2):151-156.
  47. Beck AD, Wilson WR, Lynch MG, Lynn MJ, Noe R. Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Am J Ophthalmol 1998 Nov;126(5):648-657.
  48. Manners T, Salmon JF, Barron A, Willies C, Murray AD. Trabeculectomy with mitomycin C in the treatment of posttraumatic angle recession glaucoma. Br J Ophthalmol 2001 Feb;85(2):159-163.
  49. Noble J, Derzko-Dzulynsky L, Rabinovitch T, Birt C. Outcome of trabeculectomy with intraoperative mitomycin C for uveitic glaucoma. Can J Ophthalmol 2007 Feb;42(1):89-94.
  50. Panek WC, Holland GN, Lee DA, Christensen RE. Glaucoma in patients with uveitis. Br J Ophthalmol 1990 Apr;74(4):223-227.
  51. Kaburaki T, Koshino T, Kawashima H, Numaga J, Tomidokoro A, Shirato S, Araie M. Initial trabeculectomy with mitomycin C in eyes with uveitic glaucoma with inactive uveitis. Eye (Lond) 2009 Jul;23(7):1509-1517.
  52. Kiuchi Y, Sugimoto R, Nakae K, Saito Y, Ito S. Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica 2006;220(6):383-388.
  53. Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol 2009 May;147(5):912-918.
  54. Maestrini HA, Cronemberger S, Matoso HD, Reis JR, Mérula RV, Filho AD, Sakurai E, Ferreira GA. Late needling of flat filtering blebs with adjunctive mitomycin C: efficacy and safety for the corneal endothelium. Ophthalmology 2011 Apr;118(4):755-762.
  55. Iwach AG, Delgado MF, Novack GD, Nguyen N, Wong PC. Transconjunctival mitomycin-C in needle revisions of failing filtering blebs. Ophthalmology 2003 Apr;110(4):734-742.
  56. Mardelli PG, Lederer CM Jr, Murray PL, Pastor SA, Hassanein KM. Slit-lamp needle revision of failed filtering blebs using mitomycin C. Ophthalmology 1996 Nov;103(11):1946-1955.
  57. Cheng JW, Cai JP, Li Y, Wei RL. Intraoperative mitomycin C for nonpenetrating glaucoma surgery: a systematic review and meta-analysis. J Glaucoma 2011 Jun-Jul;20(5):322-326.
  58. Alvarado JA, Hollander DA, Juster RP, Lee LC. Ahmed valve implantationwith adjunctive mitomycin C and 5-fluorouracil: long-term outcomes. Am J Ophthalmol 2008 Aug;146(2):276- 284.
  59. Costa VP, Azuara-Blanco A, Netland PA, Lesk MR, Arcieri ES. Efficacy and safety of adjunctive mitomycin C during Ahmed Glaucoma Valve implantation: a prospective randomized clinical trial. Ophthalmology 2004 Jun;111(6):1071-1076.
  60. Al-Mobarak F, Khan AO. Two-year survival of Ahmed valve implantation in the first 2 years of life with and with out intraoperative mitomycin C. Ophthalmology 2009 Oct;116(10):1862-1865.
  61. Abraham LM, Selva D, Casson R, Leibovitch I. The clinical applications of fluorouracil in ophthalmic practice. Drugs 2007;67(2):237-255.
  62. Khaw PT, Sherwood MB, MacKay SL, Rossi MJ, Schultz G. Five-minute treatments with fluorouracil, floxuridine and mitomycinhave long-term effects on human Tenon's capsule fibroblasts. Arch Ophthalmol 1992 Aug;110(8):1150-1154.
  63. Smith S, D'Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Ophthalmol 1994 Sep;118(3):332-337.
  64. Palanca-Capistrano AM, Hall J, Cantor LB, Morgan L, Hoop J, WuDunn D. Long-term outcomes of intraoperative 5-f luorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. Ophthalmology 2009 Feb;116(2):185-190.
  65. Singh K, Mehta K, Shaikh NM, Tsai JC, Moster MR, Budenz DL, Greenfield DS, Chen PP, Cohen JS, Baerveldt GS, et al. Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology 2000 Dec;107(12):2305-2309.
  66. Towler HM, McCluskey P, Shaer B, Lightman S. Longterm follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma. Ophthalmology 2000 Oct;107(10):1822-1828.
  67. Heuer DK, Parrish RK 2nd, Gressel MG, Hodapp E, Desjardins DC, Skuta GL, Palmberg PF, Nevárez JA, Rockwood EJ. 5-Fluorouracil and glaucoma filtering surgery. III. Intermediate follow-up of a pilot study. Ophthalmology 1986 Dec;93(12):1537-1546.
  68. Ruderman JM, Welch DB, Smith MF, Shoch DE. A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol 1987 Sep;104(3):218-224.
  69. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 1996 Apr;121(4):349-366.
  70. Goldenfeld M, Krupin T, Ruderman JM, Wong PC, Rosenberg LF, Ritch R, Liebmann JM, Gieser DK. 5-Fluorouracil in initial trabeculectomy. A prospective, randomized, multicenter study. Ophthalmology 1994 Jun;101(6):1024-1029.
  71. Tsai JC, Feuer WJ, Parrish RK 2nd, Grajewski AL. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 1995 Jun;102(6):887-893.
  72. Rockwood EJ, Parrish RK 2nd, Heuer DK, Skuta GL, Hodapp E, Palmberg PF, Gressel MG, Feuer W. Glaucoma filtering surgery with 5-Fluorouracil. Ophthalmology 1987 Sep;94(9):1071-1078.
  73. Leyland M, Bloom P, Zinicola E, McAlister J, Rassam S, Migdal C. Single intraoperative application of 5-Fluorouracil versus placebo in low-risk trabeculectomy surgery: a randomized trial. J Glaucoma 2001 Dec;10(6):452-457.
  74. Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow-up. Ophthalmology 2000 Jun;107(6):1184- 1190.
  75. Wong TT, Khaw PT, Aung T, Foster PJ, Htoon HM, Oen FT, Gazzard G, Husain R, Devereux JG, Minassian D, et al. The Singapore 5-fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3 years. Ophthalmology 2009 Feb;116(2):175-184.
  76. Wong MH, Husain R, Ang BC, Gazzard G, Foster PJ, Htoon HM, Wong TT, Oen FT, Khaw PT, Seah SK, et al. The Singapore 5-fluoro uracil trial: intraocular pressure outcomes at 8 years. Ophthalmology 2013 Jun;120(6):1127-1134.
  77. WuDunn D, Cantor LB, Palanca-Capistrano AM, Hoop J, Alvi NP, Finley C, Lakhani V, Burnstein A, Knotts SL. A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy. Am J Ophthalmol 2002 Oct;134(4):521-528.
  78. Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil vs mitomycin C. Am J Ophthalmol 1997 Jan;123(1):48-53.\
  79. Lamping KA, Belkin JK. 5-fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995 Jan;102(1):70-75.
  80. Anand N, Khan A. Long-term outcomes of needle revision of trabeculectomy blebs with mitomycin C and 5-fluorouracil: a comparative safety and efficacy report. J Glaucoma 2009 Sep;18(7):513-520.
  81. Greenfield DS, Liebmann JM, Jee J, Ritch R. Late-onset bleb leaks after glaucoma filtering surgery. Archives of Ophthalmology 1998 Apr;116(4):443-447.
  82. Lamping KA, Bellows AR, Hutchinson BT, Afran SI. Longterm evaluation of initial filtration surgery. Ophthalmology 1986 Jan;93(1):91-101.
  83. Katz GJ, Higginbotham EJ, Lichter PR, et al. Mitomycin C vs 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995 Sep;102(9):1263-1269.
  84. Ticho U, Ophir A. Late complications after glaucoma filtering surgery with adjunctive 5-fluorouracil. Am J Ophthalmol 1993 100. Storr-Paulsen T, Norregaard JC, Ahmed S, Storr-Paulsen A. Apr 15;115(4):506-510.
  85. Dhingra S, Khaw PT. The moorfields safer surgery system. Middle East Afr J Ophthalmol 2009 Jul;16(3):112-115.
  86. Wells AP, Cordeiro MF, Bunce C, Khaw PT. Cystic bleb formationand related complications in limbus vs fornix-based conjunctivalflaps in pediatric and young adult trabeculectomy with mitomycin C. Ophthalmology 2003 Nov;110(11): 2192-2197.
  87. Cordeiro MF, Constable PH, Alexander RA, Bhattacharya SS, Khaw PT. Effect of varying the mitomycin C treatment area in glaucoma filtration surgery in the rabbit. Investigative Ophthalmol and Visual Science 1997 Jul;38(8):1639-1646.
  88. Kupin TH, Juzych MS, Shin DH, Khatana AK, Olivier MM. Adjunctive mitomycin C in primary trabeculectomy in phakic eyes. Am J Ophthalmol 1995 Jan;119(1):30-39.
  89. Zacharia PT, Deppermann SR, Schuman JS. Ocular hypotony after trabeculectomy with mitomycin C. Am J Ophthalmol 1993 Sep 15;116(3):314-326.
  90. Costa VP, Wilson RP, Moster MR, Schmidt CM, Gandham S. Hypotony maculopathy following the use of topical mitomycin C in glaucoma filtration surgery. Ophthalmic Surgery 1993 Jun;24(6):389-394.
  91. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992 Nov 15;114(5):544-553.
  92. Seah SK, Prata JA Jr, Minckler DS, Baerveldt G, Lee PP, Heuer DK. Hypotony following trabeculectomy. J Glaucoma 1995 Apr;4(2):73-79.
  93. Katz LJ, Cantor LB, Spaeth GL. Complications of surgery in glaucoma. Early and late bacterial endophthalmitis following glaucoma filtering surgery. Ophthalmology 1985 Jul;92(7): 959-963.
  94. Greenfield DS, Suner IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. Archives of Ophthalmology 1996 Aug;114(8): 943-949.
  95. Yamamoto T, Sawada A, Mayama C, et al. The 5-year incidence of bleb-related infection and its risk factors after filteringsurgeries with adjunctive mitomycin C: collaborative bleb- related infection incidence and treatment study 2. Ophthalmology 2014 May;121(5):1001-1006.
  96. Zahid S, Musch DC, Niziol LM, Lichter PR. Risk of endophthalmitis and other long-term complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS).Am J Ophthalmol 2013 Apr;155(4):674-680.
  97. Higginbotham EJ, Stevens RK, Musch DC, et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology 1996 Apr;103(4):650-656.
  98. Song A, Scott IU, Flynn HW Jr, Budenz DL. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology 2002 May;109(5):985-991.
  99. The fluorouracil filtering surgery study group. Fluorouracil filtering surgery study one-year follow-up. Am J Ophthalmol 1989 Dec 15;108(6):625-635.
  100. Storr-Paulsen T, Norregaard JC, Ahmed S, Storr-Paulsen A. Corneal endothelial cell loss after mitomycin C-augmented trabeculectomy. J Glaucoma 2008 Dec;17(8):654-657.
  101. McDermott ML, Wang J, Shin DH. Mitomycin and the human corneal endothelium. Archives of Ophthalmology 1994 Apr;112(4):533-537.
  102. Blake DA, Sahiner N, John VT, et al. Inhibition of cell proliferation by mitomycin C incorporated into P(HEMA) hydrogels J Glaucoma 2006 Aug;15(4):291-298.
  103. Sahiner N, Kravitz DJ, Qadir R, et al. Creation of a drugcoated glaucoma drainage device using polymer technology: in vitro and in vivo studies. Archives of Ophthalmology 2009 Apr;127(4):448-453.
  104. Liang L, Xu XD, Zhang XZ, Feng M, Peng C, Jiang FG. Prevention of filtering surgery failure by subconjunctival injection of a novel peptide hydrogel into rabbit eyes. Biomedical Materials 2010 Aug;5(4):045008 (p. 8).
  105. Xu XD, Liang L, Chen CS, et al. Peptide hydrogel as an intraocular drug delivery system for inhibition of postoperative scarring formation. ACS applied materials and interfaces 2010 Sep;2(9):2663-2671.
  106. Chen HY, Ge J, Guo Y, Jin CJ, Lan YQ, Lin MK. The inhibition effect of photodynamic on human Tenon capsule fibroblast cells. (Zhonghua yan ke za zhi) Chinese J Ophthalmology 2003 Mar;39(3):160-162.
  107. Shao T, Li X, Ge J. Target drug delivery system as a new scarring modulation after glaucoma filtration surgery. Diagnostic Pathology 2011;6:64.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.